Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1260-1263

  Biedenbach, Douglas J ^a   Bell, Jan M ^b   Sader, Helio S ^a   Turnidge, John D ^b   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALBAVANCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, BACTERIAL; EUROPE; GRAM-POSITIVE BACTERIA; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PACIFIC OCEAN; QUALITY CONTROL; TEICOPLANIN; VANCOMYCIN;

EID: 62949149461     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01453-08     Document Type: Article

References (14)

1. Biedenbach, D. J., J. E. Ross, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2007. Activity of dalbavancin tested against Staphylococcus spp. and β-he- molytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45:998-1004.
2. Clinical and Laboratory Standards Institute, 2006. Approved standard M7-A7. 7th ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Gordon, K, A., M, L. Beach, D. J. Biedenbach, R. N. Jones, P. R. Rhomberg, and A. H. Mutnick. 2002. Antimicrobial susceptibility patterns of beta-he- molytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:157-162.
5. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan.2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
6. Jones, R. N., T. R. Fritsche, H. S. Sader, and B. P. Goldstein. 2005. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 17:593-600.
7. Jones, R. N., J. M. Streit, and T. R. Fritsche. 2004. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Anti- microb. Agents 23:197-199.
8. Lin, S. W., P. L. Carver, and D. D. DePestel. 2006. Dalbavancin: a new option for the treatment of gram-positive infections. Ann. Pharmacother. 40:449- 460.
9. Moet, G. J., R. N. Jones, D. J. Biedenbach, M. G. Stitwell, and T. R. Fritsche.2007. Contemporaiy causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57:7-13.
10. Pope, S. D., and A. M, Roecker. 2006. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26:908-918.
11. Rennie, R., L, Koeth, R. Jones, T. Fritsche, C, Knapp, S, Killian, and B. Goldstein. 2007. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin. a new glycopeptide agent? J. Clin. Microbiol. 45:3151-3154.
12. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37:1298-1303.
13. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.
14. Streit, J. M., H. S. Sader, T. R. Fritsche, and R. N. Jones. 2005. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53:307-310.